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adenocarcinomas (ADCs) and 122 patients with squa-
mous cell carcinomas (SQCCs) were also analyzed. All the 
tumors were stained with antibodies for 10 RTKs: c-Kit, 
EGFR, IGF1R, KDR, ERBB2, FGFR1, c-Met, ALK, RET, 
and ROS1.
Results The LCNEC and SCLC patients exhibited simi-
lar clinicopathological characteristics. The IHC scores for 
each RTK were almost equivalent between the LCNEC and 
SCLC groups, but they were significantly different from 
those of the ADC or SQCC groups. In particular, c-Kit 
was the only RTK that was remarkably expressed in both 
LCNECs and SCLCs. On the other hand, about 20 % of the 
HGNEC tumors exhibited strongly positive RTK expres-
sion, and this rate was similar to those for the ADC and 
SQCC tumors. Intriguingly, strongly positive RTKs were 
almost mutually exclusive in individual tumors.
Conclusions Compared with ADC or SQCC, LCNEC and 
SCLC had similar expression profiles for the major RTKs. 
The exclusive c-Kit positivity observed among HGNECs 
suggests that c-Kit might be a distinctive RTK in HGNEC.
Keywords High-grade neuroendocrine carcinoma · 
Receptor tyrosine kinase · Immunohistochemical staining · 
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Introduction
Large cell neuroendocrine carcinoma (LCNEC) is dis-
tinguished from small cell lung carcinoma (SCLC) based 
on its histological criteria, that is, a larger cell size, abun-
dant cytoplasm, prominent nucleoli, vesicular nuclei or 
coarse chromatin, and a polygonal rather than a fusiform 
shape (Battafarano et al. 2005). Despite these differences, 
LCNEC and SCLC share many similarities in terms of not 
Abstract 
Background As the comprehensive genomic analysis of 
small cell lung cancer (SCLC) progresses, novel treatments 
for this disease need to be explored. With attention to the 
direct connection between the receptor tyrosine kinases 
(RTKs) of tumor cells and the pharmacological effects of 
specific inhibitors, we systematically assessed the RTK 
expressions of high-grade neuroendocrine carcinomas of 
the lung [HGNECs, including SCLC and large cell neu-
roendocrine carcinoma (LCNEC)].
Patients and methods Fifty-one LCNEC and 61 SCLC 
patients who underwent surgical resection were enrolled 
in this research. As a control group, 202 patients with 
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only immunohistochemistry, but also clinical character-
istics (Gupta et al. 2004; Asamura et al. 2006; Fernandez 
and Battafarano 2006; Gollard et al. 2010; Nakachi et al. 
2010; Dobashi et al. 2011; Li et al. 2012; Peifer et al. 
2012; Rudin et al. 2012; Sun et al. 2012). Consequently, 
these lesions are often grouped together as high-grade neu-
roendocrine carcinoma (HGNEC). LCNEC also shares 
genetic alterations that are commonly seen in SCLCs, such 
as TP53, RB1, and EP300 (Jones et al. 2004; Peifer et al. 
2012; Rudin et al. 2012; CLCGP-NGM 2013), suggesting a 
genetic similarity to SCLC. However, little is known about 
the differences in the protein expression profiles between 
these two histological types.
In addition, only fragmented information on therapeu-
tically relevant gene alterations is available for HGNECs. 
Two reports regarding integrative genomic analyses of 
SCLC have shown that transcriptional deregulation (for 
example, via RB1, SOX2, and MYC family members and 
chromatin modifiers) might have a role in its biology.
(Peifer et al. 2012; Rudin et al. 2012) To date, however, 
attempts to develop targeted therapies for these transcrip-
tional deregulations have had limited success. Recently, 
we performed whole-exome sequencing of 51 Asian SCLC 
patients and demonstrated that the SCLC genome pos-
sessed distinguishable genetic features in the PI3K/AKT/
mTOR pathway (Umemura et al. 2014). In this report, both 
gene mutations and copy number variations were analyzed, 
and genetic alterations in various targetable well-known 
receptor tyrosine kinase (RTK) genes were detected, 
but these variations were not correlated with the genetic 
changes in the PI3K/AKT/mTOR pathway, and their func-
tional roles have remained unclear.
As already known, RTKs are the initial signaling gate on 
the cell membrane. Given their pivotal roles in tumor ini-
tiation and progression, RTKs have become one of the most 
prominent target families for drug development (IASLC 
2009; Umemura et al. 2014). Therefore, in the present study, 
we analyzed the protein expressions of the major RTKs 
of the HGNEC tumors, which we examined using whole-
exome sequencing, and compared them with those of ade-
nocarcinoma (ADC) and squamous cell carcinoma (SQCC) 
to identify biologically distinctive alterations in HGNECs.
Materials and methods
Patient selection
Between 1992 and 2012, a total of 51 consecutive LCNEC 
and 61 consecutive SCLC patients underwent surgical 
resections in National Cancer Center Hospital East, Japan; 
these patients were enrolled in the present study. As a con-
trol group, 202 adenocarcinoma (ADC) and 122 squamous 
cell carcinoma (SQCC) patients who underwent surgery 
between 2010 and 2012 were also analyzed. We obtained 
the clinicopathological data of all the enrolled patients 
from our database and analyzed the results.
Histological studies
The surgical specimens had been fixed in 10 % formalin or 
100 % methyl alcohol. The specimens were sliced through 
the largest diameter of the primary tumor, and all the sec-
tions were embedded in paraffin. Serial 4-μm sections were 
stained using the hematoxylin and eosin (HE) method, the 
Alcian blue-periodic acid-Schiff (AB-PAS) method for the 
detection of cytoplasmic mucin production, or the Elastica 
van Gieson (EVG) or the Victoria-blue van Gieson (VVG) 
method for the detection of elastic fibers. All the histologi-
cal materials included in this series were reviewed by two 
pathologists (Y.M. and G.I.). The pathological stage was 
determined based on the 7th edition TNM classification of 
the International Union Against Cancer (UICC) (IASLC 
2009). We diagnosed the histological types of lung cancer 
according to The World Health Organization (WHO) clas-
sification of lung cancer (Travis et al. 2004). LCNEC was 
distinguished from SCLC based on this classification. Mor-
phologically, LCNEC is characterized by neuroendocrine 
morphologic features (organoid nesting, trabecular growth, 
and rosette-like and palisading patterns), large tumor cells 
(three times larger in diameter than a small resting lym-
phocyte) with a low nuclear/cytoplasmic ratio, numerous 
nucleoli, a high mitotic rate (>10 in 10 high-power fields), 
and a large degree of necrosis. The neuroendocrine features 
were confirmed for all LCNEC and SCLC patients by the 
presence of at least one positive neuroendocrine marker, 
such as chromogranin, synaptophysin, or CD56.
Antibodies and immunohistochemical staining for RTK
Tissue microarray (TMA) slides of all the enrolled tumors 
were used for immunohistochemical staining (IHC). We 
retrieved two cores with diameters of 2 mm from a selected 
paraffin block from each tumor and utilized them for the 
TMA. The companies from which we purchased the anti-
bodies and the detailed IHC procedures are shown in Sup-
plemental Table 1. The antibodies targeted the following 
10 RTKs: c-Kit, EGFR, insulin-like growth factor 1 recep-
tor (IGF1R), kinase insert domain receptor (KDR), human 
epidermal growth factor receptor 2 (ERBB2), fibroblast 
growth factor receptor 1 (FGFR1), c-MET, anaplastic lym-
phoma kinase (ALK), RET, and ROS1. The reason that we 
chose these 10 RTKs in this research was because they had 
been widely reported, and their IHC tests were also well 
validated in our laboratory. Immunostaining was performed 
on 4-μm paraffin-embedded tissue sections. The slides 
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were deparaffinized in xylene and dehydrated in a graded 
ethanol series, and endogenous peroxidase was blocked 
with 3 % hydrogen peroxide in absolute methyl alcohol. 
After epitope retrieval, the slides were washed with phos-
phate-buffered saline and incubated overnight with the pri-
mary antibodies. For the secondary antibodies, the slides 
were subsequently incubated with EnVision™ (Dako, 
Glostrup, Denmark) for 30 min at room temperature fol-
lowed by the color reaction developed in 2 % 3, 3′-diam-
inobenzidine in 50 mM Tris buffer (pH 7.6) containing 
0.3 % hydrogen peroxidase. The reaction products were 
stained with diaminobenzidine (DAB) and were counter-
stained with hematoxylin. ERBB2 and c-MET were stained 
using the Ventana Ultraview DAB detection kit in Ventana 
Benchmark XT stainer (Ventana Medical Systems, Tuc-
son, AZ, USA). The IHC staining of ALK and ROS1 was 
performed according to previous reports (Nitta et al. 2013; 
Yoshida et al. 2013a).
Immunohistochemical scoring
All the stained tissue sections were semiquantita-
tively scored and evaluated independently under a light 
microscope by two pathologists (Y.M. and G.I.) who had 
no knowledge of the patients’ clinicopathological data. 
The labeling scores for the tumor cells were calculated by 
multiplying the percentage of positive tumor cells in each 
lesion (0–100 %) by the staining intensity level (0 = nega-
tive, 1 = weak, 2 = strong). When the scores differed, the 
pathologists re-examined the slides together, discussed the 
results, and reached an agreement. In this research, tumors 
with an IHC score of 20–90 were defined as “weakly posi-
tive,” since the median score of each RTK in each histo-
logical type was 20 or less. On the other hand, tumors with 
an IHC score of 100 or more were defined as “strongly 
positive,” because such tumors belonged to the top 10 % 
of highest scores for each RTK (Fig. 1 and Supplemental 
Figure 1).
Statistical analysis
The Mann–Whitney U test or the Fisher’s exact test was 
used to test differences between two groups for statisti-
cal significance. All the reported P values were two-sided, 
and the significance level was set at <0.05. Overall sur-
vival and recurrence-free survival were calculated using 
Fig. 1  Immunohistochemical 
staining of LCNEC, SCLC, 
ADC, and SQCC. LCNEC and 
SCLC were strongly stained for 
c-Kit, while ADC and SQCC 
were negative. IGF1R was 
weakly positive in LCNEC and 
SCLC and strongly positive 
in SQCC. ADC was negative 
for IGF1R. On the other hand, 
c-Met was negative in LCNEC 
and SCLC and strongly positive 
in ADC. SQCC was weakly 
positive for c-Met
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the Kaplan–Meier method, and significance was tested 
using a log-rank test. The analyses were performed using 
the SPSS 11.0 statistical software program (Dr. SPSS II for 
Windows, standard version 11.0; SPSS Inc., Chicago, IL, 
USA).
Results
Clinicopathological features of LCNEC and SCLC
The clinicopathological characteristics of the LCNEC, 
SCLC, ADC, and SQCC patients are shown in Table 1. Of 
the enrolled patients, 43 (84 %), 50 (82 %), 120 (59 %), 
and 112 (92 %) of the patients with LCNEC, SCLC, ADC, 
and SQCC were men, respectively. Smoking history was 
observed in 50 (98 %), 59 (98 %), 128 (64 %), and 121 
(99 %) of the patients with LCNEC, SCLC, ADC, and 
SQCC, respectively. No significant differences in the clin-
icopathological characteristics of the patients with LCNEC 
and those with SCLC were seen. Compared with the ADC 
group, significantly more men and smokers were observed 
in the LCNEC and SCLC group (all P < 0.01). As for the 
pStage, no significant differences were observed among 
the four types of lung cancers. Vascular invasion and lym-
phatic permeation were significantly more frequent in 
patients with LCNEC or SCLC than in patients with ADC 
(P < 0.01).
Immunohistochemical staining scores for each 
histological type
Figure 2 and Table 2 show the immunohistochemical stain-
ing score (IHC score) for each RTK (c-Kit, EGFR, IGF1R, 
Table 1  Clinicopathological characteristics of LCNEC and SCLC, compared with those of adenocarcinoma and squamous cell carcinoma
Statistically significant values are indicated in bold (p ≤ 0.05)
LCNEC and SCLC: from 1992 to 2011
ADC and SQCC: from 2010 to 2012
Chi-square test
LCNEC SCLC ADC SQCC
n = 51 n = 61 n = 202 n = 122
Gender: men (%) 43 (84) 50 (82) 120 (59) 112 (92)
Age: median (range) 69 (53–84) 67 (22–86) 68 (40–93) 70 (42–85)
Smoking: ever (%) 50 (98) 59 (97) 128 (64) 121 (99)
Pack-year ≥50 26 (51) 24 (39) 46 (23) 71 (58)
pStage I 31 (62) 34 (56) 131 (65) 47 (39)
 II 10 (19) 14 (23) 36 (18) 44 (36)
 III 10 (19) 11 (18) 31 (15) 31 (25)
 IV 0 2 (3) 4 (2) 0
Pleural invasion 20 (39) 19 (31) 77 (38) 56 (41)
Vascular invasion 39 (76) 52 (85) 84 (42) 83 (68)
Lymphatic permeation 18 (35) 23 (38) 31 (15) 28 (23)
P value LCNEC versus 
SCLC
LCNEC versus ADC LCNEC versus SQCC SCLC versus ADC SCLC versus SQCC
Men 0.80 <0.01 0.15 <0.01 0.05
Age 0.84 0.52 0.56 0.36 0.06
Smoking 1.00 <0.01 0.54 <0.01 0.21
PY ≥ 50 0.25 <0.01 0.38 0.01 0.02
pStage I–II versus III–IV 0.94 0.71 0.41 0.48 0.54
Pleural invasion 0.43 0.90 0.42 0.39 0.08
Vascular invasion 0.33 <0.01 0.26 <0.01 0.01
Lymphatic permeation 0.85 <0.01 0.10 <0.01 0.04
Fig. 2  Immunohistochemical staining scores for each histologi-
cal type. Compared with ADC, both LCNEC and SCLC had signifi-
cantly higher scores for c-Kit, IGF1R, and KDR and lower scores for 
ERBB2, FGFR1, c-Met, and ROS1. Compared with SQCC, they had 
significantly higher scores for c-Kit, KDR, and RET and lower scores 
for EGFR and IGF1R. Therefore, c-Kit was the only RTK that was 
remarkably expressed in LCNEC and SCLC, compared with both 
ADC and SQCC
▸
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KDR, ERBB2, FGFR1, c-Met, ALK, RET, and ROS1) in 
each histological type. Three points of interest were identi-
fied from these scores. First, no significant differences in 
the IHC scores for each RTK were observed between the 
LCNEC and the SCLC tumors. Second, the IHC scores 
for the LCNEC and SCLC tumors were significantly dif-
ferent from those for the ADC and SQCC tumors. Specifi-
cally, both the LCNEC and the SCLC tumors had signifi-
cantly higher scores for c-Kit, IGF1R, and KDR and lower 
scores for ERBB2, FGFR1, c-Met, and ROS1, compared 
with the ADC tumors. When compared with the SQCC 
tumors, the LCNEC and the SCLC tumors had significantly 
higher scores for c-Kit, KDR, and RET and lower scores 
for EGFR and IGF1R. Thirdly, c-Kit was the only RTK that 
was remarkably expressed in LCNEC and SCLC tumors, 
compared with both ADC and SQCC tumors.
RTK expressions in individual patients according 
to each histological type
We also analyzed the RTK expressions in individual 
patients and plotted each RTK score for individual cases in 
Fig. 3. “Strongly positive (dark blue in Fig. 3),” “weakly 
positive (light blue),” and “negative” in this figure were 
determined according to the criteria described in the 
“Methods” section. This figure and Supplemental Table 2A 
revealed that more than 80 % of the tumors in each histo-
logical type had at least one strongly or weakly positive 
RTK. The number of tumors with two or more positive 
RTKs was 28 (55 %) for the LCNEC tumors, 23 (56 %) for 
the SCLC tumors, 131 (65 %) for the ADC tumors, and 82 
(67 %) for the SQCC tumors. The numbers of LCNEC and 
SCLC tumors with two or more positive RTKs were nearly 
Fig. 2  continued
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identical (P = 0.93), but the numbers tended to be lower for 
LCNEC and SCLC tumors than for ADC or SQCC tumors 
(Supplemental Table 2B). Supplemental Table 3 shows the 
number of patients with positive RTKs according to each 
histological type. These numbers were similar between the 
LCNEC and SCLC tumors for all the RTKs, but the num-
bers for the LCNEC and SCLC tumors differed signifi-
cantly from those for the ADC and SQCC tumors for some 
RTKs. Compared with the ADC tumors, the frequency of 
positive RTKs among the LCNEC and SCLC tumors was 
significantly higher for c-Kit (LCNEC: 49 %, SCLC: 47 %, 
and ADC: 3 %), IGF1R (LCNEC: 31 %, SCLC: 28 %, and 
ADC: 5 %), and KDR (LCNEC: 29 %, SCLC: 38 %, and 
ADC: 1 %) and lower for ERBB2 (LCNEC: 6 %, SCLC: 
2 %, and ADC: 17 %), FGFR1 (LCNEC: 2 %, SCLC: 0 %, 
and ADC: 35 %), c-Met (LCNEC: 2 %, SCLC: 6 %, and 
ADC: 43 %), and ROS1 (LCNEC: 0 %, SCLC: 0 %, and 
ADC: 40 %). Compared with SQCC, on the other hand, 
the frequency of positive RTKs among the LCNEC and 
SCLC tumors was significantly higher for c-Kit (LCNEC: 
49 %, SCLC: 47 %, and SQCC: 4 %) and lower for EGFR 
(LCNEC: 41 %, SCLC: 31 %, and SQCC: 69 %), IGF1R 
(LCNEC: 31 %, SCLC: 28 %, and SQCC: 62 %), and 
c-Met (LCNEC: 2 %, SCLC: 6 %, and SQCC: 14 %). These 
tables and Fig. 3 revealed that the distributions of positive 
RTKs were similar for the LCNEC and SCLC tumors but 
differed from those for the ADC and SQCC tumors.
Regarding the strongly positive RTKs, the LCNEC 
group exhibited strongly positive c-Kit in five tumors, 
EGFR in three, IGF1R in two, and KDR and ERBB2 in 
one each; thus, a total of 12 (24 %) LCNEC tumors had 
some kind of strongly positive RTK. The SCLC group 
had strongly positive c-Kit in four tumors, EGFR in two, 
IGF1R in two, and KDR in three, for a total of 10 (16 %) 
SCLC tumors with a strongly positive RTK (one tumor was 
strongly positive for both c-Kit and IGF1R). On the other 
hand, the ADC group exhibited strongly positive EGFR 
in five tumors, ERBB2 in five, c-Met in 16, ALK in three, 
RET in one, and ROS1 in six, for a total of 33 (16 %) ADC 
tumors with a strongly positive RTK. One ADC tumor was 
positive for both EGFR and c-Met, and two tumors were 
positive for both c-Met and ROS1. The SQCC group exhib-
ited strongly positive EGFR in 17 tumors, IGF1R in two, 
and KDR in five, for a total of 20 (16 %) SQCC tumors 
with a strongly positive RTK. Four tumors were positive 
for both EGFR and KDR, but none of the tumors had three 
Table 2  Immunohistochemical 
staining score due to 
histological type
Statistically significant values are indicated in bold (p ≤ 0.05)
Mann–Whitney’s U test
RTKs LCNEC (n = 51)
Mean
SCLC (n = 61)
Mean
Adc (N = 202)
Mean
Sqcc (N = 122)
Mean
c-Kit 31.7 ± 5.3 32.2 ± 5.2 0.9 ± 0.7 1.6 ± 1.6
EGFR 26.4 ± 10.9 20.6 ± 7.7 15.9 ± 3.9 44.3 ± 8.7
IGF1R 18.2 ± 7.6 17.7 ± 8.1 2.7 ± 1.1 33.5 ± 6.5
KDR 18.1 ± 7.7 22.5 ± 8.2 0.7 ± 0.6 19.4 ± 6.0
ERBB2 5.5 ± 7.8 1.4 ± 2.8 10.0 ± 3.6 0.5 ± 1.0
FGFR1 1.8 ± 2.2 0.2 ± 0.4 19.1 ± 4.0 1.7 ± 1.5
c-Met 1.1 ± 8.3 2.0 ± 7.6 28.6 ± 4.1 5.9 ± 5.4
ALK 0 0.2 ± 3.9 3.0 ± 3.1 0
RET 10.5 ± 5.5 8.7 ± 4.0 13.2 ± 3.1 0.8 ± 0.6
ROS1 0.3 ± 0.4 0.2 ± 0.2 23.6 ± 4.7 2.3 ± 1.4










c-Kit 0.75 <0.01 <0.01 <0.01 <0.01
EGFR 0.23 0.28 <0.01 0.45 <0.01
IGF1R 0.74 <0.01 0.03 <0.01 <0.01
KDR 0.73 <0.01 0.17 <0.01 0.06
ERBB2 0.12 <0.01 0.95 <0.01 0.95
FGFR1 0.27 <0.01 0.86 <0.01 0.49
c-Met 0.91 <0.01 0.78 <0.01 0.84
ALK 0.99 0.68 0.50 0.78 0.96
RET 0.97 0.96 <0.01 0.94 <0.01
ROS1 0.99 <0.01 0.20 <0.01 0.17
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or more strongly positive RTKs among any of the histologi-
cal types. Of interest, Fig. 3 shows that each tumor with a 
strongly expressed RTK was almost mutually exclusive.
RTK expression and genomic alterations
Supplemental Figure 2 shows the relationship between the 
EGFR mutation status and RTK expression in ADC. The 
EGFR mutation status was assessed using the PCR invader 
assay for 147 patients. Of them, 58 (39 %) harbored EGFR 
mutations: 40 had point mutations in exon 21 (L858R), 16 
had exon 19 deletions, and 2 had minor mutations. Three 
of the four (75 %) cases with strongly positive EGFR 
expression also harbored EGFR mutations, while 20 of the 
21 (95 %) cases with strongly positive non-EGFR-RTK 
expression did not have EGFR mutations. As for SQCC, 
the EGFR mutation status was examined in 25 of the 122 
(20 %) enrolled patients, but EGFR mutations were not 
identified in any of the cases.
On the other hand, Supplemental Figure 3 shows the 
relationship between RTK expression and genomic altera-
tions in SCLC. The genomic alteration data for these SCLC 
tumors were extracted from our previous report (Umemura 
et al. 2014). Minimal correlations were observed between 
a strong positivity for RTK expression and genomic altera-
tions. However, one patient with strong c-Kit expression 
had an in-frame deletion and a copy number gain in the 
KIT gene.
Overall survival of patients with LCNEC or SCLC
The overall survival (OS) rates of the LCNEC and SCLC 
groups are shown in Supplemental Figure 4. The median 
follow-up period was 61 months. The 3-year OS rates for 
the LCNEC patients and for the SCLC patients were both 
66 %. No significant difference in the OS was seen between 
the LCNEC group and the SCLC group (P = 0.53). When 
LCNEC and SCLC were grouped together and considered 
as HGNEC, the 3-year OS of the patients with HGNEC 
tumors with a strongly positive RTK (n = 22) and that of 
patients with those without it (n = 90) was 70 and 63 %, 
respectively; these percentages were not significantly dif-
ferent (P = 0.17) (Supplemental Figure 5). The 3-year OS 
rates of patients with and those without c-Kit positivity 
were 69 % and 63 %, respectively, and these values were 
also not significantly different (P = 0.57) (Supplemental 
Figure 6).
Discussion
We performed an extensive RTK expression study for all 
four major histological types of lung cancer, focusing on 
HGNEC. Intriguingly, the overall RTK expression pat-
terns of LCNEC and SCLC were similar, but they were 
quite different from those for ADC or SQCC. The similar-
ity between LCNEC and SCLC has long been described 
since the concept of LCNEC was first proposed in the 
1990s (Travis et al. 1991, 1998a, b). Based on the morpho-
logical features of LCNEC and SCLC, many reports have 
suggested a similarity in their clinical behaviors (Asamura 
et al. 2006; Kinoshita et al. 2013) and sensitivities to chem-
otherapy (Le Treut et al. 2013; Niho et al. 2013). Jones 
et al. (2004) also reported that they could not distinguish 
LCNEC from SCLC based on gene expression profiling. 
From this aspect, our analysis of the protein expression lev-
els of major RTKs supports the past consensus.
In the present research, we analyzed the RTK expres-
sion levels in individual patients and plotted each RTK 
score for individual cases, since diversity in the expression 
levels was observed in individual cases even among those 
with the same histological type. This analysis revealed that 
about 20 % of LCNEC and SCLC tumors had some kind of 
strongly stained RTK, such as c-Kit, EGFR, IGF1R, KDR, 
or ERBB2. Interestingly, most of these strongly staining 
RTKs were mutually exclusive, evoking the oncogenic 
driver mutations (EGFR, KRAS, ALK, and ROS1) observed 
in lung adenocarcinoma. Additionally, we examined the 
relationship between the EGFR mutation status and RTK 
expression in ADC and showed that strongly positive non-
EGFR–RTKs tended to be mutually exclusive with EGFR 
mutations. We anticipate that this exclusiveness might 
reflect the importance of these highly expressed RTKs for 
tumor proliferation, survival, or invasiveness.
In this study, one strongly positive ERBB2 tumor 
existed in the LCNEC group, but no strongly positive 
ERBB2 tumors were seen in the SCLC group. According 
to a recent report from The Clinical Lung Cancer Genome 
Project (CLCGP) and Network Genomic Medicine (NGM) 
(CLCGP-NGM 2013), a total of two (5 %) LCNEC tumors 
with ERBB2 amplification, but no SCLC tumors, have 
been reported, consistent with the present findings. The 
identification of LCNEC tumors with high ERBB2 expres-
sion levels suggests that a subset of these tumors might be 
Fig. 3  Distribution of RTK positivity in individual patients accord-
ing to each histological type. Dark blue indicates a strongly positive 
RTK (IHC score of 100 or more), light blue indicates a weakly posi-
tive RTK (IHC score of between 20 and 90), and white indicates RTK 
negativity (IHC score of 0 or 10). More than 80 % of the tumors in 
each histological type had at least one strongly or weakly positive 
RTK. The distributions of positive RTKs were similar in LCNEC 
and SCLC but varied from those of ADC and SQCC. Regarding the 
strongly positive RTKs, the LCNEC group had a total of 12 (24 %) 
tumors with some type of strongly positive RTK. The SCLC group 
had 10 (16 %), the ADC group had 33 (16 %), and the SQCC had 
20 (16 %) strongly positive RTKs. The strongly positive RTKs were 
almost mutually exclusive in individual tumors
◂
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sensitive to ERBB2 inhibitors, similar to ERBB2-positive 
gastric cancer and breast cancer (Asaoka et al. 2011; Stern 
2012; Kumler et al. 2014).
Some LCNEC and SCLC tumors have been reported to 
exhibit FGFR1 amplification (Peifer et al. 2012); however, 
no LCNEC or SCLC tumors that were strongly positive for 
FGFR1 were observed in our study. Although the amplifi-
cation of FGFR1 is reportedly predominant in squamous 
cell carcinomas, the association with overexpression was 
inconclusive (Pros et al. 2013). Further examination of 
FGFR1 alterations is needed.
The histological type-specific findings in the present 
study were in accordance with previous reports of a high 
frequency of c-Kit expression in HGNEC (Pelosi et al. 
2004a, b, Dy et al. 2005; Schneider et al. 2010; Lu et al. 
2012), EGFR expression in SQCC (Mountzios et al. 2010; 
Pirker et al. 2012; Jiang et al. 2013), and ALK expression 
in a minority (three of 202 tumors, 1.5 %) of ADC tumors 
(Chen et al. 2012; Park et al. 2012; Nitta et al. 2013). Of 
note, the expression of c-Kit was considerably higher in 
HGNEC than in ADC or SQCC, suggesting its biological 
importance for tumorigenesis in HGNEC. High expres-
sion levels of c-Kit in LCNEC have also been previously 
reported (Araki et al. 2003; Rossi et al. 2003; Casali et al. 
2004; Pelosi et al. 2004a, b, Rossi et al. 2005; Lopez-Mar-
tin et al. 2007; Schneider et al. 2010; Lu et al. 2012). Simi-
lar to our findings, Rossi et al. (2003) reported that c-KIT 
was frequently expressed in both SCLC and LCNEC, but 
not in ADC or SQCC. However, two phase II studies using 
imatinib, a c-Kit inhibitor, failed to demonstrate any clini-
cal benefit even among selected SCLC patients harboring 
c-Kit-expression (Dy et al. 2005; Schneider et al. 2010). 
Unlike the situation for gastrointestinal stromal tumors 
(GIST), activating mutations in the KIT gene were mini-
mally associated with the immunohistochemical expres-
sion of c-Kit in HGNEC. Actually, Rossi et al. reported 
that c-Kit was strongly expressed in 52 of the 83 LCNECs 
(62.7 %), but no activating mutation was detected in the 
KIT gene. We combined the current results with our pre-
vious data for whole-exon sequencing and a copy num-
ber analysis of SCLC samples (Umemura et al. 2014) 
and observed a similar tendency. Nevertheless, one SCLC 
case with strong c-Kit expression also had a mutation and 
amplification of the KIT gene. This rare case might be a 
candidate for targeted therapy, and IHC for c-Kit might be 
useful for patient screening. On the other hand, in imatinib-
resistant GIST, the PI3K/AKT/mTOR pathway is a major 
contributor to proliferation and survival (Floris et al. 2013). 
This pathway has also been proposed as an actionable sign-
aling cascade that is active in SCLC (Arriola et al. 2008; 
Ilic et al. 2011). This finding implies that a combined treat-
ment with PI3K/AKT/mTOR inhibitor might be potentially 
effective for increasing the sensitivity to c-Kit inhibitors 
in HGNEC. In addition to tyrosine kinase inhibitors, anti-
bodies are expected to be effective for tumor cells overex-
pressing target RTKs. A novel treatment using anti-c-kit 
antibody has been attempted in vitro (Yoshida et al. 2013b). 
Further studies will require the clarification of specific 
biological features and the development of c-Kit-targeted 
therapies.
As for the survival of patients with LCNEC and those 
with SCLC, the OS rates for both histological types were 
not significantly different, similar to the results of previ-
ous reports (Asamura et al. 2006; Kinoshita et al. 2013). 
Furthermore, the OS curve of HGNEC patients with RTK 
positivity was not significantly different from those without 
RTK positivity (Supplemental Figs. 2 and 3). The reasons 
for the similarity in OS curves were thought to include the 
small population of strongly positive RTKs, the short fol-
low-up periods, the contributions of other RTK, and driver 
oncogenes that were not assessed in the present study. We 
did not find any significant effect of c-Kit expression on 
survival, similar to the results of previous reports (Rossi 
et al. 2005; Lopez-Martin et al. 2007). However, Casali 
et al. (2004) reported that c-Kit expression in LCNEC was 
a negative prognostic factor. Further investigation of pos-
sible correlations in larger studies is warranted.
In conclusion, LCNEC and SCLC are relatively simi-
lar, compared with ADC and SQCC, even at the protein 
expression level. Based on this background, the develop-
ment of molecular-targeted agents for SCLC and LCNEC 
could be combined into the development of treatments for 
“HGNEC” (Pelosi et al. 2004b; Schneider et al. 2010; Sun 
et al. 2012; CLCGP-NGM 2013). Although RTK positiv-
ity cannot be used as the sole criterion for targeted thera-
pies for HGNEC, strongly positive RTKs were observed in 
a mutually exclusive manner, suggesting their biological 
importance for tumorigenesis in HGNEC. In the future, we 
plan to perform both expression and genomic analyses of 
RTK in non-resectable advanced HGNEC tumors, in addi-
tion to surgically resected samples.
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